Official ESCRS | European Society of Cataract & Refractive Surgeons
Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert


Search Title by author or title

Assessment of treatment performance of latent form of choroidal neovascularization

Poster Details

First Author: A.Yusupov UZBEKISTAN

Co Author(s):                        

Abstract Details


To compare efficacy of subthreshold transpupillary thermotherapy (TTT) and anti-VEGF therapy in treatment of latent forms of chronic neovascularization (CNV) in patients with exudative age-related macular degeneration.


JV 'SIHAT KO'Z' Eye Clinic


Results of treatment of 42 patients with exudative AMD with latent form of CNV. The first group included 20 patients (20 eyes) who underwent a course of anti-VEGF therapy, consisting of 3 intravitreal injections of ranibizumab with interval between the injections of 1 month. The remaining 22 patients (22 eyes) who received subthreshold TTT, were included into second study group.


The results show that usage of anti-VEGF therapy has little effectiveness and is not accompanied with elevation of visual functions in treatment of hidden form of chronic neovascularization and detachment of the retina pigment epithelium. The low effectiveness was because of sub pigment localization of process that blocks maximum penetration of drug in the affected area. Transpupillary thermotherapy in subfoveal hidden form of chronic neovascularization allowed to reach a full regress of neovascularization in 54,5% cases and elevation of functional activities of the eye with improvement electro genesis of the retina after carried out treatment.


TTT results in complete regression of hidden CNV in 54.5% of cases, slows down the pace of development of pathological process in 22.7% of cases and contributes to preservation of visual functions of macular area statistically significant at higher level during the year compared with results of course of anti-VEGF therapy.

Financial Disclosure:


Back to Poster listing